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Abstract
Background: Accurate safety monitoring in HIV vaccine trials is vital to eventual licensure and consequent uptake of products.
Current practice in preventive vaccine trials, under the HIV Vaccine Trials Network (HVTN), is to capture related side effects
in a hardcopy tool. The reconciliation of this tool, 2 weeks after vaccination at the safety visit, is time consuming, laborious, and
fraught with error. Unstructured Supplementary Service Data (USSD), commonly used to purchase airtime, has been suggested
for collection of safety data in vaccine trials. With saturated access to mobile phones in South Africa, this cheap, accessible tool
may improve accuracy and completeness of collected data and prove feasible and acceptable over the hardcopy tool.
Objective: The objective of our study is to develop and implement a USSD tool for real-time safety data collection that is
feasible and acceptable to participants and staff, allowing for a comparison with the hardcopy tool in terms of completeness and
accuracy.
Methods: This feasibility study is being conducted at a single study site, the Centre for the AIDS Programme of Research in
South Africa eThekwini Clinical Research site, in South Africa. The feasibility study is nested within a parent phase 1/2a preventive
HIV vaccine trial (HVTN 108) as an open-label, randomized controlled trial, open to all consenting parent trial participants.
Participants are randomly assigned in a 1:1 ratio to the hardcopy or USSD tool, with data collection targeted to the third and
fourth injection time points in the parent trial. Online feasibility and acceptability surveys will be completed by staff and participants
at the safety visit. We will itemize and compare error rates between the hardcopy tool and the USSD printout and associated
source documentation. We hypothesize that the USSD tool will be shown to be feasible and acceptable to staff and participants
and to have superior quality and completion rates to the hardcopy tool.
Results: The study has received regulatory approval. We have designed and developed the USSD tool to include all the data
fields required for reactogenicity reporting. Online feasibility and accessibility surveys in both English and isiZulu have been
successfully installed on a tablet. Data collection is complete, but analysis is pending.
Conclusions: Several HIV preventive vaccine trials are active in Southern Africa, making tools to improve efficiencies and
minimize error necessary. Our results will help to determine whether the USSD tool can be used in future vaccine studies and
can eventually be rolled out.
Trial Registration: ClincalTrials.gov NCT02915016; https://clinicaltrials.gov/ct2/show/NCT02915016 (Archived by WebCite
at http://www.webcitation.org/71h0cztDM)
Registered Report Identifier: RR1-10.2196/9396
(JMIR Res Protoc 2018;7(10):e175)  doi: 10.2196/resprot.9396
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Introduction
Rationale
Despite the gains made in the provision of antiretroviral
treatment and, more recently, prevention globally, in 2015 there
were 1.8 million new infections worldwide. South Africa has
the biggest antiretroviral treatment program in the world, with
approximately 3.4 million people being treated [1]. In November
2015, South Africa registered emtricitabine/tenofovir disoproxil
fumarate (Truvada) for preexposure prophylaxis in key
populations yet, in 2016 alone, approximately 270,000 incident
infections occurred [2]. A safe, effective HIV vaccine is still
seen as the solution to epidemic control and, ultimately,
elimination.
Safety monitoring in HIV vaccine clinical trials is vital, from
early-phase safety and immunogenicity testing, to late-phase
efficacy testing and eventual licensure of candidate vaccines.
An essential part of safety monitoring is the collection of side
effects data reported by participants after they have received a
study product and for 3 to 7 days after leaving the clinic. All
preventive HIV vaccine trials collect reactogenicity data: this
is a set of known and expected injection site and systemic
symptoms and signs that are related to the vaccine. Unexpected
side effects (classified as adverse events) are also collected on
study-specific case report forms (CRFs). The duration of the
reactogenicity period depends on the protocol, and adverse event
data collection periods are defined per protocol, depending on
the seriousness of the event. In sub–Saharan Africa, a suite of
trials in response to the modest results of the RV144 trial [3]
has been launched to progress a modified HIV clade C–specific
vaccine candidate to licensure and to deepen the understanding
of the mechanisms of immune protection against HIV.
Concurrently, several early-phase HIV vaccine trials, 2 efficacy
trials, and a proof-of-concept neutralizing antibody infusion
trial are being conducted. The possibility of increased occurrence
of safety events is thus greater in these populations and
simultaneously demands more accurate, efficient methods of
data collection.
Vaccine Uptake and Efficacy
Public perception and tolerance of licensed vaccine risk indicates
that, in the absence of a direct threat from disease, some people
will not undergo vaccination unless absolute safety can be
assured [4]. If a successful HIV vaccine candidate is licensed
in the future, there is a risk that people may avoid vaccination
due to safety concerns. A systematic review of barriers to
participating in an HIV vaccine trial analyzed common themes
between studies and found that vaccine side effects and safety
were noted as barriers to participation [5]. The collection of
accurate safety data is vital to address these concerns. In a
systematic review of 50 randomized controlled vaccine trials
in developing countries, consistent documentation was key to
the successful implementation of international safety standards
in resource-poor settings [6]. Modern technologies, including
short message service (SMS) and mobile phone apps, were
recommended as possibly facilitating the monitoring of vaccine
safety in remote areas, where access to internet connectivity
may not always be possible [6]. This technology would allow
for real-time data collection, offering an improvement over the
hardcopy tool. Standardization of safety reporting across
multiple sites in developing countries was borne out in a
systematic review of safety data reporting in vaccine trials for
malaria, tuberculosis, and HIV, which focused partly on methods
used to collect and report side effects [7]. This review noted
imprecision and inconsistency of body temperature reporting,
which is a key objective safety parameter. The proper collection
and documentation of unexpected side effects also allows for
regulators and sponsors alike to link uncommon side effects
across trials and sites, enabling the identification of sporadic,
serious side effects [7].
The Hardcopy Tool
Research staff collect reactogenicity data initially at the study
site before and up to 60 minutes after vaccination on CRFs. For
the remainder of the reporting period, participants collect data
off-site on a hardcopy tool. This demands extensive, intensive
training of participants on completion of this tool (in the
language of their choice) and training on the use of a
thermometer and ruler, for temperature and injection site
reactogenicity assessments, respectively. Participants are also
taught to objectively grade the severity of symptoms using a
standardized set of symptom criteria. Research staff are directed
to contact participants by telephone daily (in early-phase
protocols) or after 3 or 7 days (for later-phase protocols) to
check on participants’ health, collect and objectively grade
symptoms, and provide refresher training as needed. Objective
grading determines whether a symptom is mild, moderate,
severe, or life-threatening and facilitates clinical decision
making and symptom management on continuation of
vaccinations per participant and protocolwide. Staff document
these data directly onto corresponding CRFs on working days
and in a site-developed document outside of clinic operational
hours. This is then transcribed to CRFs on the next working
day. At the 2-week postvaccination safety visit, research staff
review the CRFs, hardcopy tool, and site-developed source
document (if applicable) with each participant to ensure that
CRF data are accurate. This process is repeated for each
vaccination visit within the protocol.
This exercise remains fraught with error from a multitude of
sources: daily data collection is not directly attributable to
participants, and there is no evidence that data are completed
contemporaneously; participants are often uncontactable at the
agreed-upon time or do not have the hardcopy tool with them
when contacted by staff to complete CRFs; participants may
not return the hardcopy tool to the site at the safety visit or at
all, and data have to be reconstructed based on participant recall
2 weeks later; participants tend to grade symptoms subjectively
despite training; many hardcopy tool entries are incomplete or
incorrect; and staff need to document each error in detail
between the relevant documentation, making the time and labor
the task consumes proportional to the number of errors. In
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addition, national research regulators may consider all or part
of the hardcopy tool as a source document, and errors such as
incorrect dates, overwriting, and entry of redundant or unclear
information by the participant must be documented in explicit
detail. If not, the site risks incurring serious findings by external
monitors, directly affecting protocol quality metrics. For
moderate reactogenicity and other adverse events, the site relies
on participant-initiated contact to determine whether a clinic
visit is required as mandated by the protocol. If this is missed,
a protocol deviation must be reported to the sponsor, regulator,
and ethics committee. More importantly, participant safety may
be severely compromised if an unreported symptom fulfills a
pause rule for the study, when all further vaccinations at all sites
may be held, pending a risk assessment.
The alternative to the systems detailed above would be daily
clinic visits for the duration of the reactogenicity period for
each vaccination time point. This would increase the cost of
participant reimbursements, negatively affect travel and
convenience for participants, and increase the research site’s
workload for the day. The conduct of multiple studies per site,
necessitating a process efficiency system to reduce visit duration,
does not support this labor-intensive and inefficient process.
Mobile Health and Unstructured Supplementary
Service Data
Mobile health (mHealth) is the practice of medicine and public
health supported by mobile devices, which have the potential
to facilitate alerts, reminders, and data collection, substantially
reducing the burden on health care systems [8-11]. Unstructured
Supplementary Service Data (USSD) is a tool that transfers
messages directly over the mobile operator network, allowing
for an exchange between mobile phones and a network app. It
is accessed by user request, making use of short codes or text
strings to trigger certain services and facilitate high-speed,
interactive, session-based communication. The text string, up
to 160 characters long, can be used to establish a new session
or to continue an established session, with asterisk (*) and hash
(#) codes signifying the beginning and end of the request,
respectively. Most importantly, it is accessible on basic mobile
phones. In Botswana, research recommendations in mHealth
have alluded to the successful use of USSD by health care
workers to retrieve treatment guidelines [12].
South Africa is highly ranked fifth in the world for mobile data
usage [13,14], with more active subscriber identity module cards
than people and 128% active mobile connections among the
population [15]. By mid-2013, total mobile phone subscriptions
were estimated at over 68 million [13]. USSD could prove useful
to implement real-time reactogenicity data collection, having
several advantages courtesy of its menu-based platform, namely,
speed and responsivity, affordability, real-time entry and access,
automation, user initiation, and simultaneous mass usage. It is
affordable and accessible, with the total cost of a typical session
depending on duration of the session (20 cents per 20 seconds;
US $0.074 dollar = 100 cents or 1 R). It allows only “yes” or
“no” responses, thus shortening the session length and improving
affordability. SMS text messaging is managed manually, can
cost up to 100 cents per message, and would need to be initiated
by the provider. Responses submitted by USSD are
automatically deleted on the device, complying with data
confidentiality requirements of Good Clinical Practice and the
US Food and Drug Administration’s Code of Federal
Regulations Part 11. One of the cornerstones of the South
African National Department of Health’s mHealth strategy [16]
commits the government to providing an mHealth
implementation plan to strengthen research and development.
In this study, we propose the collection of reactogenicity and
adverse event data using a customized USSD tool, with the
objectives of developing and implementing a basic mobile
phone-based USSD tool for the collection of reactogenicity
data, establishing feasibility and acceptability among research
staff and participants, and determining whether the accuracy
and completeness is superior to the hardcopy tool. Piloting this
technology in the research setting in a developing country such
as South Africa in an early-phase trial will allow for
optimization of the system to facilitate collection of safety data
across multiple sites, in late-phase, large-scale studies and
eventual programmatic rollout.
The South African regulator follows South African Good
Clinical Practice Guidelines [17], which confirms the
compliance of USSD data collection as acceptable.
Methods
Study Design
This is an open-label, randomized controlled trial under the HIV
Vaccine Trials Network (HVTN) nested in the parent HVTN
108 trial, a phase 1/2a clinical trial to evaluate the safety and
immunogenicity of HIV clade C DNA, and of MF59- or
AS01B-adjuvanted clade C Env protein in various combinations,
in healthy, HIV-uninfected adult participants. The parent study
has a series of 4 vaccination time points in a 6-month period:
at months 0, 1, 3, and 6. The study will use 2 consecutive
vaccination time points, namely months 3 and 6, to implement
the USSD tool, with postvaccination feasibility and acceptability
surveys at the 2-week postvaccination safety visits. At months
0 and 1, all participants complete the hardcopy tool for
reactogenicity assessment. The intervention is a
purpose-designed, study-specific USSD tool that collects all
the protocol-mandated reactogenicity data collected by the
hardcopy tool. At the time of initiating this paper, the USSD
tool and electronic surveys had been developed and approved,
and enrollment was ongoing.
Setting
The Centre for the AIDS Programme of Research in South
Africa (CAPRISA) eThekwini Clinical Research Site (ECRS)
was chosen as the sole site for this study.
Approvals
The parent and this study were approved by the University of
Kwazulu-Natal’s Biomedical Research Ethics Committee; in
addition, the parent study was approved by the University of
Kwazulu-Natal’s Institutional Biosafety Committee, the South
African Medicines Control Council, and the Department of
Agriculture, Forestry and Fisheries. The South African National
Clinical Trials Registry number for the parent study is
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NCT02915016. This pilot trial did not meet the US Food and
Drug Administration requirements for trial registration. We
received further review and approvals for this study from the
HVTN 108 protocol team, the HVTN Regulatory Affairs office,
HVTN Initiatives Program’s review board, and HVTN Scientific
Governance Committee.
Statistical Considerations
Accrual
Up to 30 slots may be allocated to the CAPRISA ECRS for the
parent study. Recruitment for this nested study will target
enrolling all consenting, healthy, HIV-uninfected adult
participants aged 18 to 40 years enrolled in the parent study at
the CAPRISA ECRS in a 1:1 ratio to the hardcopy or USSD
tool.
Sample Size Calculations
We estimated the power for detecting a reduction in error rates
for the USSD relative to the hardcopy tool arm via simulation.
We assumed that the total number of errors for a single
participant at a single visit would follow a Poisson distribution
whose mean we determined by the study arm the participant
was assigned to and differs depending on whether the participant
was randomly assigned to use the USSD or the hardcopy tool.
Data were simulated assuming 2 possible error rates for the
hardcopy group and 2 possible group sizes, and the error rate
for the USSD group was varied over a small range of values.
The simulated data were fit using a Poisson regression model
consisting of an intercept and a term for the study group, and
the coefficient of the study group was tested for equality with
0.
Study End Points
We will calculate error rates for both the USSD and hardcopy
tool for completeness (defined as an entry that should have been
completed, but was not) and for accuracy (the level of agreement
between the data collected either by hardcopy tool or by USSD
and the entries on the reactogenicity CRFs following a
discussion with the participant to confirm final data; staff
transcription errors and participant completion errors will also
be taken into account). This will be expressed as errors per 100
pages completed.
Conditions Under Which Power is Computed
For means, the reported error count range for the hardcopy tool
is 5 (“very good”) to 26 (“very bad”). We used a calculated
average (mean) error rate, likely lying in the range of 13 to 17,
to compute power (Table 1).
For sample size, we used a maximum possible enrollment into
this ancillary study of 30 participants, based on the expected
slot allocation for HVTN 108, which would result in 15
participants assigned to each of the USSD and hardcopy arms.
Since we are unlikely to achieve the maximum enrollment, we
computed power for 2 levels of enrollment that reflect poor and
good consent rates. The poor level assumes that a total of 20
participants consent to the ancillary study—an expected 10 per
group—which is a 56% consent rate. The good level of
enrollment assumes that 30 participants will consent—an 83%
rate—and would give us an expected 15 participants per group.
Since the data consist of repeated measures from individual
participants, they require modelling that accounts for the
correlation between measurements from the same person, and
one standard way is to use mixed-effects models. Count data
require us to use the generalized linear mixed-effects model
framework, and we will employ the negative binomial family
(rather than the Poisson) for the extra flexibility it provides.
Our model will contain at a minimum a fixed effect for the
method of data collection (USSD or hardcopy tool) and a
random effect for participant. When writing the statistical
analysis plan, we may consider models containing additional
fixed-effect terms (eg, for sex, visit number), as well as more
complex random-effect structures, and we will incorporate terms
as appropriate based on model fit criteria such as the Akaike
information criterion. Inference on the difference between
methods will be made by testing whether the estimate of the
collection method parameter is significantly different from 0 at
the .05 level.
Table 1. Power for differential sample size and error rates.
Power to detect difference in means between HCTb and USSDc groups (%)
Reduction in error ratea, n (%)
Mean errors per participant per visit
15 participants per group10 participants per groupUSSDHCT
55403 (18)1417
80654 (24)1317
94835 (29)1217
99956 (35)1117
69513 (23)1013
90804 (31)913
99955 (38)813
aUnstructured Supplementary Service Data vs hardcopy too.
bHCT: hardcopy tool.
cUSSD: Unstructured Supplementary Service Data.
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Discontinuation and Early Study Termination
The number and percentage of participants who discontinue
vaccination and thus who terminate the nested study early will
be tabulated by reason and intervention arm in the pilot study.
Data Management
For participants enrolled into the hardcopy tool arm, the tool,
CRFs, and other study documentation are the source for the
reactogenicity data over the 7-day postvaccination reporting
period.
For those randomly assigned to the USSD arm, the tool database
printouts, CRFs, and other study documentation are the source
for reactogenicity data. All participants randomly assigned to
the USSD arm will also receive a backup hardcopy tool in the
event of system errors that cannot be overcome with site support;
these will also be used as source, if applicable. The tool database
printouts of reactogenicity reports are transcribed onto CRFs
by research staff.
Tools
Unstructured Supplementary Service Data Tool
Development
The tool has been designed through a collaborative effort
between the service provider Channel Mobile (Cape Town,
South Africa) in consultation with the investigators and the
parent study HVTN Clinical Safety Specialist team. The tool
name is pMOTAR (pilot study of Mobile Technology to Assess
Reactogenicity) for ease of reference for participants and
research staff.
The following design features facilitate data input and collection.
(1) All the data elements are included in the hardcopy tool of
the parent study. (2) As data are entered on the mobile phone,
uploads to the database are immediate. (3) Participants can
access the system multiple times in one day, to facilitate
completion of incomplete sessions. (4) A “preserve state”
enables participants to continue from the last active screen where
they left off, if they were previously timed out or could not
complete the session for any reason. (5) Only minimal responses
are required for ease of use, for example, selection of a number
corresponding to the symptom, followed by selection of a
number corresponding to the objective grading. (6) Participant
responses indicative of potential safety events, such as a “yes”
response to any expected or unexpected symptoms followed by
free text to denote the symptom, will also be available to staff
through contemporaneous alerts from the system routed to
designated staff mobile phone numbers. (7) Participants can
choose between 2 languages: English and Zulu. (8) Risk of harm
is minimal, as confidentiality is assured in that entered data
cannot be saved to the handset or transferred to another handset,
and are automatically deleted following submission; only
research staff have access to the entered data in the tool
database. (9) Reverse billing is applied, such that participants
can log on to the system even if they have no airtime. At the
end of the session, the cost of the session is charged to the
research site. This ensures ease of access to and use of pMOTAR
with no possibility of the participant running out of airtime
during a session. (10) Automated SMS reminders are sent out
at 08:00, 12:00, and 15:00 if the system is not accessed and the
tool is not completed. (11) Double entries have not been
disallowed so as to facilitate entry of updated measurements or
missed entries from a previous day that have been captured on
a hardcopy tool, perhaps because of connectivity issues on the
day of measurement. Each entry will trigger an SMS text
message to alert study staff, who can call the participant
immediately to clarify the reason and document the same in a
chart note, such that duplicate entries in the database can be
explained and analyzed appropriately.
Unstructured Supplementary Service Data Tool Database
The following tool database features facilitate contemporaneous
access of information by research staff. (1) Printouts from the
tool database will serve as source documentation for completion
of CRFs. (2) Real-time access to the tool database allows staff
to review data in a timely manner and determine whether
immediate action to assess a participant’s response is required
to clarify an entry or to facilitate a site visit to assess safety. (3)
Reports can be downloaded and printed, and usage can be
tracked based on mobile phone number patterns from the tool
database. (4) An audit trail and an automatic daily backup of
the tool database is made to an external drive at 04:00. (5)
Physical servers are hosted at a secure data center with failovers
(switching to a redundant or standby computer server on the
failure or abnormal termination of the current server) to the
Amazon cloud (Amazon.com, Inc, Seattle, WA, USA) and
Azure (Microsoft Corporation, Redmond, WA, USA).
Unstructured Supplementary Service Data Tool Specifics
The flow of the USSD app service for reactogenicity symptom
assessment is as follows. First, a mobile user initiates the service
by dialing the USSD string defined by the service provider
Figures 1-4 show sample screen flow strings.
Second, the USSD app server receives the service request from
the user and responds by sending the user a menu of options.
(1) The first menu allows selection of the preferred language,
either 1 for English or 2 for Zulu; the user responds by selecting
option 1 or 2 and then presses <SEND>. If the incorrect option
is selected, the user selects <CANCEL> and reselects. (2) The
next screen includes a greeting and a request to enter a 4-digit
unique identifying code provided by the research staff. (3) Once
the code is entered, an invitation to capture the temperature is
loaded, allowing the participant to enter a measurement to 1
decimal point. (4) After the participant selects <SEND>, an
automated menu of numbered local symptoms and choice of
responses is sent to the user. Local symptoms also reflect
whether vaccinations are given in the right or left upper arm,
or both. (5) If the participant selects either redness or swelling
at the injection site, they will be prompted to enter measurements
in centimeters, initially from top to bottom, and then from side
to side. (6) If the participant responds by making a single
selection of another symptom, this will trigger an automated
response from the app, which sends out the selection of grading
(minimal, some, or major) by the participant. (7) Once the
participant selects <SEND>, they are returned to the original
symptom selection screen to select any other symptoms that
may be experienced. (8) If no other symptoms have been
experienced, the participant selects <NEXT>, then the system
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loads the selection of systemic symptoms for completion. (9) If
the participant responds by making a single selection of a
symptom, this will trigger an automated response from the app,
which sends out the selection of grading (minimal, some, or
major, which equates to minimal, moderate, and severe) by the
participant. (10) Once the grading for the selected symptom is
selected and the participant selects <SEND>, they will be taken
back to the original systemic symptom selection screen.
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Figure 1. The Sample Unstructured Supplementary Service Data Tool (string 1).
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Figure 2. Part 1 of the Sample Unstructured Supplementary Service Data Tool (string 2).
(11) The last prompt from the system is for the occurrence of
any other unexpected symptoms, not previously listed on any
screens, and allows for free entry of text to describe the
symptom. (12) Each response occurs in a matter of seconds, in
quick succession, and in real time, and the participant is not
able to skip any screens to get to the end.
Third, once a participant selects <SEND>, the entered data are
automatically uploaded to the tool database and simultaneously
deleted from the handset, ensuring confidentiality.
Fourth, the app automatically ends the session when <FINISH>
is selected, then delivers a “Thank you” message to confirm
completion of all questions to the participant.
Mobile phone numbers of consenting participants are obtained
from the locator information of the parent study records and
linked to unique confidential identifying 4-digit codes, which
are assigned to the participant during training on the USSD
program and used by the participant to access the app.
The Hardcopy Tool
The hardcopy tool (Figures 5-7) is provided by the research
staff to the participant, who is trained in how to complete this
tool on the day of vaccination, before leaving the clinic. If a
participant experiences difficulty completing the tool at home,
they are informed to contact the site for support or inform the
staff during the daily call. Research staff telephone participants
either daily or according to the protocol directive, with the
expectation that the participant has access to the hardcopy tool
at the time of the call. Research staff will ask the participant to
share temperature and any local injection site lesion
measurements with the research staff member, who then enters
this information either directly onto the CRF on a working day
or into a site-developed document for use on nonworking days
off-site.
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Figure 3. Part 2 of the Sample Unstructured Supplementary Service Data Tool (string 2).
pMOTAR Clinical Procedures
Informed Consent and Screening Procedures
Research staff obtain written informed consent in the preferred
language of the participant and prior to any screening
procedures.
Participants are screened at a visit prior to the third vaccination
in the parent study vaccination series, followed by an assessment
of eligibility, as per the inclusion and exclusion criteria. Selected
information from the parent study, namely informed consent
form and locator information, are accessed to confirm eligibility.
The participant identifying number from the parent study is
used to link data from this ancillary study to the parent study.
Enrollment and Randomization
Participants are enrolled and randomly assigned on the same
day as the third vaccination, following a review and
confirmation of eligibility, revisiting the informed consent form
(as needed). Participants in the intervention arm are assigned a
unique 4-digit code to access the USSD tool; participants in the
control arm follow procedures for the parent study.
The randomization system uses computer-generated random
numbers, so that if 30 participants are enrolled, there will be 15
in each arm. Sealed opaque randomization envelopes are
provided to the study coordinator for storage, to be opened in
sequential order. After the envelopes are opened, the date and
time of opening the envelopes, as well as the research staff
member’s name, are documented on the envelope. This
information is then noted on the randomization sheet.
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Figure 4. Part 3 of the Sample Unstructured Supplementary Service Data Tool (string 2).
Figure 5. Sample hardcopy tool (page 1).
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Figure 6. Sample hardcopy tool (page 2).
All participants are trained in the use of either the hardcopy or
USSD tool, depending on arm assignment, and in the use of the
thermometer and ruler. The participants in the intervention arm
are trained in the use of the hardcopy tool as a backup; this
training is repeated at the next vaccination time point (3 months
after enrollment). Likewise, all participants, irrespective of arm
assignment, receive site contact details to assist with tool
completion (if they experience difficulty once off-site) or to
report additional problems.
Eligibility Criteria
Participants are healthy, HIV-uninfected (seronegative) adults
enrolled in the parent study, who comprehend the purpose of
the study and have provided written informed consent.
The inclusion criteria are (1) HIV-uninfected male and female
adults, 18 to 40 years of age, who are enrolled in the parent
study at the CAPRISA ECRS; (2) participants who have
confirmed full access to a compatible mobile phone and willing
to receive text reminders; (3) participants who have the ability
and willingness to provide informed consent; (4) participants
who are English or Zulu speaking; and (5) participants who
have demonstrable text message literacy.
The exclusion criteria are (1) participants who have missed
vaccination visits at month 0 or 1 in the parent study; (2)
participants who have had vaccination visits discontinued
(temporarily or permanently); (3) participants who have mobile
phones on a contractual basis, paying a monthly service and
airtime fee over 24 months from purchase, as reverse billing is
not compatible with this system; and (4) participants who have
any significant condition or process that renders the participant
incapable of participating that would interfere with or serve as
a contraindication to protocol adherence, assessment of safety
or reactogenicity, or a volunteer’s ability to give informed
consent as per the investigator’s decision.
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Figure 7. Sample hardcopy tool (page 3).
Blinding
Participants and site staff are unblinded as to participant
intervention group assignments for the 2 arms of this study but
remain blinded to the treatment assignment of the parent study.
The Statistical Data Management Centre staff for the parent
study are blinded to the group assignments in this nested study
to maintain the integrity of the blinding for the parent study.
Follow-Up
Follow-up visits are aligned with the 2-week postvaccination
safety visit of the parent study at each designated vaccination
time point. At these scheduled safety visits, in addition to the
parent study procedures, a computerized feasibility and
acceptability survey is completed on a tablet, by both
participants and research staff members. Participants have
separate surveys for either the USSD tool (Multimedia Appendix
1) or hardcopy tool (Multimedia Appendix 2), while staff have
one survey that compares the two (Multimedia Appendix 3).
Reactogenicity Assessments
The reactogenicity assessment period for the parent study is 7
full days following each vaccination (Tables 2 and 3). For
participants assigned to the hardcopy tool arm, participants
complete the tool off-site daily for 8 days (day 0 to day 7, day
0 being the night of the vaccination). Research staff contact
participants daily for the first 4 days only (a phone call is made
to check on the reactogenicity assessment done the day before)
during the assessment period to determine whether the objective
grading, as per the US National Institute of Allergy and
Infectious Diseases Division of AIDS (DAIDS) adult and
pediatric toxicity table [18], is confirmed. If the grading is
confirmed, a repeat call the next day will be made to determine
whether the symptom is resolving. If the symptom is not
resolving, the participant will be brought into the clinic for a
JMIR Res Protoc 2018 | vol. 7 | iss. 10 | e175 | p. 13https://www.researchprotocols.org/2018/10/e175/
(page number not for citation purposes)
Mngadi et alJMIR RESEARCH PROTOCOLS
XSL•FO
RenderX
clinician assessment within 48 hours of onset of the symptom,
as per the protocol. Participants document day 4 to 7 data on
the tool without daily telephone review by the staff and return
the tool at the 2-week postvaccination safety visit for review
and reconciliation with CRFs and other site documentation.
Data from the day 0 to day 3 contacts are entered directly onto
the relevant CRFs during working days and into site-developed
source on nonworking days. Participants are instructed to alert
the site of any moderate reactogenicity symptoms on the day
or any unexpected adverse events, that is, symptoms not listed
in the hardcopy tool.
Table 2. Reactogenicity procedures hardcopy versus Unstructured Supplementary Service Data (USSD) tool.
USSD toolHardcopy toolReactogenicity day
Train on use of tool, thermometer, and ruler; provide unique access
code
Train on use of tool, thermometer, and rulerDay 0
Send reminder text Access database and print reactogenicity data
for day 0; transcribe onto CRFaand enter into parent study database
Call participant and complete source documentation for
reactogenicity for day 0; enter into parent study database
Day 1
Send reminder to access the USSD Access database and print reac-
togenicity data for day 1; transcribe onto CRF and enter into parent
study database
Call participant and complete source documentation for
reactogenicity for day 1; enter into parent study database
Day 2
Send reminder mail to access the USSD by bulk SMSbtext messag-
ing Access database and print reactogenicity data for day 2; tran-
scribe onto CRF and enter into parent study database
Call and complete source documentation for reactogenicity
for day 2; enter into parent study database
Day 3
Send reminder to access the USSD Access database and print reac-
togenicity data for day 3; transcribe onto CRF and enter into parent
study database
Call and complete source documentation for reactogenicity
for day 3; enter into parent study database
Day 4
Send reminder to access the USSD Access database and print reac-
togenicity data for day 4; transcribe onto CRF and enter into parent
study database
Call and complete source documentation for reactogenicity
for day 4; enter into parent study database
Day 5
Send reminder to access the USSD Access database and print reac-
togenicity data for day 5; transcribe onto CRF and enter into parent
study database
Call and complete source documentation for reactogenicity
for day 5; enter into parent study database
Day 6
Send reminder to access the USSD Access database and print reac-
togenicity data for day 6; transcribe onto CRF and enter into parent
study database
Call and complete source documentation for reactogenicity
for day 6; enter into parent study database
Day 7
Send reminder to access the USSD Access database and print reac-
togenicity data for day 7; transcribe onto CRF and enter into parent
study database
Call and complete source documentation for reactogenicity
for day 7; enter into parent study database
Day 8
aCRF: case report form.
bSMS: short message service.
Table 3. Schedule of reactogenicity assessments.
Performed byTimeDay
HIV Vaccine Trials Network clinical research site staffBaseline: before vaccination0a
HIV Vaccine Trials Network clinical research site staffEarly: 25-60 minutes after vaccination0
Unstructured Supplementary Service Data or hardcopy toolBetween early assessment and 11:59 PM0
Unstructured Supplementary Service Data or hardcopy toolBetween 12:00 AM and 11:59 PM1
Unstructured Supplementary Service Data or hardcopy toolBetween 12:00 AM and 11:59 PM2
Unstructured Supplementary Service Data or hardcopy toolBetween 12:00 AM and 11:59 PM3
Unstructured Supplementary Service Data or hardcopy toolBetween 12:00 AM and 11:59 PM4
Unstructured Supplementary Service Data or hardcopy toolBetween 12:00 AM and 11:59 PM5
Unstructured Supplementary Service Data or hardcopy toolBetween 12:00 AM and 11:59 PM6
Unstructured Supplementary Service Data or hardcopy toolBetween 12:00 AM and 11:59 PM7b
aDay of vaccination.
bNew or unresolved reactogenicity symptoms present on day 3 are followed until resolution.
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Participants allocated to the USSD arm are instructed to await
a reminder text message daily during the 7-day reactogenicity
period to access the system, enter the unique code, and complete
the tool. Any symptoms reported and graded subjectively by
the participant as moderate result in an immediate alert to
selected research staff, via SMS text message to their mobile
phones. A clinical staff member will then contact the participant
by telephone to determine whether the objective grading, as per
the DAIDS adult and pediatric toxicity table [18], is confirmed.
If it is confirmed, the file is flagged to check the grading the
next day on the database to determine whether a clinic visit is
required, as per the protocol. Alerts for unexpected symptoms
will also result in a site-initiated telephone contact to obtain
detail, grade the symptom objectively, and facilitate reporting.
Printouts from the USSD database of completed reactogenicity
assessments per day will be stored in the participant binder
following transcription onto a CRF and entry into the parent
study database. Participants complete the USSD tool daily for
8 days on the day and at the time of the assessment; no phone
calls from the site are necessary unless grade 2 or higher
symptoms are reported, repeated entries are made, or the system
shows that the participant has not logged in by 15:00 of the
same day. If a participant misses a day, they can complete the
tool retroactively for the previous day. If symptoms increase in
severity after the USSD tool has been completed, it may be
updated by the participant on the same day. Any dual entries
on a single day prompt a call from site staff to ascertain the
reason, which is documented in the site records.
Symptoms that are present at day 7 can only be detected
contemporaneously and followed up in the intervention arm,
allowing follow-up until resolution at a frequency determined
by the investigator, for example, a call a few days later to
document a resolution date. For the hardcopy tool, symptoms
present at day 7 will only be known at the follow-up safety visit
when the hardcopy tool is returned and reviewed or if the
participant proactively alerts the site staff. If the participant does
not document this in the hardcopy tool on the day that symptoms
resolve, recall bias may affect the accuracy of the data when
checked at the safety visit.
A backup hardcopy tool is given to all participants assigned to
the USSD arm, so that in the event of technical challenges that
cannot be resolved by site or provider staff, reactogenicity data
are not lost to the parent study.
Termination From the Study
Under certain circumstances, an individual participant may be
terminated from participation in this study. Specific events that
will result in early termination are (1) the participant refuses
further participation, (2) the participant no longer possesses a
mobile phone, (3) the participant is terminated from the parent
study before the vaccination series is completed, (4) the
participant relocates, (5) research staff determine that the
participant is lost to follow-up, (6) the investigator decides in
consultation with the coinvestigator to terminate participation,
for example, if a participant exhibits inappropriate behavior
toward clinic staff, and (7) any condition where termination
from the study is required by applicable regulations.
In the event of early participant termination from the ancillary
study only, research staff would consider whether the following
assessments are appropriate: a final feasibility and acceptability
questionnaire with participant consent, and a reminder in the
participant binder to provide a hardcopy tool at the next visit,
if appropriate. Data already collected would still be used in the
final analysis.
The pMOTAR may be terminated early by the determination
of the parent protocol Safety Review Team, the regulatory body,
the ethics committee, or the sponsor.
Social Impacts
Social impacts occur when participants experience any
psychological, legal, economic, or emotional harms as a direct
result of their participation in a research study; these will be
reported in the parent study. The possibility of participants in
this ancillary study experiencing social impacts is low to none,
as data are deleted from the device automatically on submission
and can only be accessed with the unique 4-digit identifying
code.
Results
The USSD app has been developed and implemented. Data
collection has been completed, and results will be published in
a primary paper.
Discussion
Implications of the Research
If collection of reactogenicity data by the USSD tool is proven
to be feasible, accessible, and superior in completeness and
accuracy to the hardcopy tool, it will leverage the use of mobile
phones and USSD apps for routine collection of reactogenicity
data in future safety and efficacy studies of vaccine candidates,
and in eventual programmatic rollout. Our experience in
development and implementation of the USSD app will allow
for adjustments to any future development and implementation
in order to reduce challenges and facilitate seamless collection
of data across all sites and studies, with appropriate training. If
successful, it will facilitate contemporaneous reactogenicity
data capture, while improving efficiency and accuracy. Accurate
safety data collection may allay participant and public fears of
side effects, leading to increased uptake of HIV vaccines in
research studies, and eventually in programmatic rollout.
Improved uptake will contribute to producing the herd immunity
required to ensure a halt to transmission in endemic areas.
Strengths and Limitations
Using a randomized controlled clinical trial to assess feasibility,
accessibility, completeness, and accuracy of the USSD is a key
strength of this study. Ensuring that the USSD and hardcopy
tools collect exactly the same safety data means that the safety
end points and potential impact on the objectives and analysis
of the parent study are not compromised. Unlike the hardcopy
tool, the USSD tool cannot be lost, even if the mobile phone is
lost, because the data having been uploaded to the database will
still be available for entry onto CRFs. From a technology
innovation perspective, the selection of USSD as the delivery
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mechanism for the intervention is an added strength, based on
accessibility on any basic mobile phone. Contemporaneous
alerts to research staff of moderate symptoms allows for
real-time follow-up to ensure symptoms are resolving and to
assess whether a clinic assessment is required or a parent study
pause rule has been met. Erroneous temperature data can also
be immediately identified, and the participant can be contacted
in a timely manner to repeat the measurement. The USSD unique
code increases the likelihood that the participant is completing
the data; the prepopulation of the user, dates, and times recorded
by the system on log-in removes duplication of data fields for
possible error, thus improving the overall quality of the data.
Data can be accessed in real time by staff and transcribed onto
CRFs, facilitating earlier entry into the parent study database.
Confidentiality is assured by autodeletion of any data entries
after completion of a USSD string and submission to the tool
database, averting the possibility of social harm. Preservation
of the last active screen builds in efficiency, so that a participant
does not double enter data for the same data field erroneously.
Limitations include that the study is not blinded, in terms of
allocation of intervention; however, data analysis staff at the
Statistical Data Management Centre will be blinded to the
allocation at the time of analysis of the parent study safety data,
thus maintaining the integrity of the parent study blinding. Errors
in USSD entry cannot be corrected in real time without a
duplicate entry on the same or next day. The USSD tool is
limited to text only, and the lack of graphical representations,
including the use of bold typeface and color, reduces the
attractiveness of the user interface, as well as the appeal to
participants who respond to graphics more easily than text.
Technological challenges when the network signal is poor or
handsets are not fully charged are also potential limitations, as
is the recruitment from only 1 site and the small sample size,
which reduces the generalizability of this study and the
reliability of the answer. It is possible that countries with lower
mobile phone coverage and access may have reduced text
literacy, which would affect the utility of the tool across regions.
Conclusion
This is, to our knowledge, the first South African randomized
clinical trial to test the feasibility and accessibility of the USSD
tool for collection of reactogenicity data in an HIV vaccine trial,
and to attempt to prove superior accuracy and completion to
the hardcopy tool. This would, we hope, improve the reliability
of safety data and possibly increase uptake of vaccines through
accurate reporting of safety data.
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